NASDAQ:CRBP - Corbus Pharmaceuticals Stock Price, Price Target & More

Corbus Pharmaceuticals trades on the NASDAQ under the ticker symbol "CRBP."

Corbus Pharmaceuticals (NASDAQ:CRBP) released its quarterly earnings results on Thursday, May, 10th. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.10) by $0.11. The biopharmaceutical company had revenue of $0.95 million for the quarter, compared to the consensus estimate of $6.25 million. Corbus Pharmaceuticals had a negative net margin of 1,040.41% and a negative return on equity of 76.01%. View Corbus Pharmaceuticals' Earnings History.

3 equities research analysts have issued 12-month price targets for Corbus Pharmaceuticals' stock. Their forecasts range from $20.00 to $32.00. On average, they anticipate Corbus Pharmaceuticals' stock price to reach $25.3333 in the next year. View Analyst Ratings for Corbus Pharmaceuticals.

Some companies that are related to Corbus Pharmaceuticals include Apellis Pharmaceuticals (APLS), Impax Laboratories (IPXL), Theravance Biopharma (TBPH), IMMURON Ltd/S (IMRN), Arrowhead Pharmaceuticals (ARWR), Alder Biopharmaceuticals (ALDR), Athenex (ATNX), Wave Life Sciences (WVE), Revance Therapeutics (RVNC), Zai Lab (ZLAB), Retrophin (RTRX), Eagle Pharmaceuticals (EGRX), Intra-Cellular Therapies (ITCI), Esperion Therapeutics (ESPR) and TG Therapeutics Inc common stock (TGTX).

News articles about CRBP stock have trended somewhat negative recently, Accern reports. Accern identifies negative and positive media coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Corbus Pharmaceuticals earned a daily sentiment score of 0.00 on Accern's scale. They also gave news stories about the biopharmaceutical company an impact score of 45.49 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.

Corbus Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.39%), ETF Managers Group LLC (4.30%), IFP Advisors Inc (2.35%), Allianz Asset Management GmbH (0.24%), Allianz Asset Management GmbH (0.24%) and Royal Bank of Canada (0.09%). Company insiders that own Corbus Pharmaceuticals stock include Alan F Holmer, Barbara White, David P Hochman, Sean F Moran and Yuval Cohen. View Institutional Ownership Trends for Corbus Pharmaceuticals.

CRBP stock was acquired by a variety of institutional investors in the last quarter, including ETF Managers Group LLC, IFP Advisors Inc, BlackRock Inc., Royal Bank of Canada, Barclays PLC, Allianz Asset Management GmbH, Allianz Asset Management GmbH and Cambridge Investment Research Advisors Inc.. Company insiders that have bought Corbus Pharmaceuticals stock in the last two years include Alan F Holmer, Barbara White, David P Hochman, Sean F Moran and Yuval Cohen. View Insider Buying and Selling for Corbus Pharmaceuticals.

Shares of CRBP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of CRBP stock can currently be purchased for approximately $5.80.

Corbus Pharmaceuticals has a market capitalization of $345.71 million and generates $2.44 million in revenue each year. The biopharmaceutical company earns $-32,420,000.00 in net income (profit) each year or ($0.65) on an earnings per share basis. Corbus Pharmaceuticals employs 47 workers across the globe.

Corbus Pharmaceuticals' mailing address is 500 River Ridge Drive, Norwood MA, 02062. The biopharmaceutical company can be reached via phone at 617-963-0100 or via email at [email protected]